EUROPE – Giant pharma company, Merck and Innervia Bioelectronics, a start-up and subsidiary of Inbrain Neuroelectronics have partnered to co-develop nex-gen smart neurostimulators for the treatment of severe chronic diseases, graphene-based bioelectronic vagus nerve therapies. Merck will leverage and build on its data science, clinical, regulatory and quality expertise as well as its bioelectronics research facilities while Innvervia will add its technical expertise in the development of graphene interfaces, device development and signal processing for clinical applications. Initially, the two companies will focus on inflammatory, metabolic and endocrine disorders by…
Read MoreMerck setting ground on bioelectronic therapy under various partnerships with its latest involving Innervia Bioelectronics
